Tags : Epidarex Capital


Macomics secures £3.2 million Seed investment led by Epidarex Capital

Novel immuno-therapies to overcome the resistance of existing cancer treatments Builds on the world-leading research into tumour associated macrophages (TAMs) Robert Haigh joins as CEO & Jane Dancer as NED Edinburgh, UK, July 14, 2020 – Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, launches today with a £3.2 million seed financing round […]Read More

Series A

LUNAC Therapeutics secures £2.65 million Series A investment led by

LUNAC Therapeutics spun out to develop next generation anticoagulants and announces Series A funding round Novel anticoagulants to minimise bleeding risk by targeting activated Factor XII Builds on a decade of academic research into Factor XII Investment round led by Epidarex Capital and University of Leeds Leeds, UK, 14 November 2019: LUNAC Therapeutics (LUNAC), a […]Read More